Added to YB: 2026-01-06
Pitch date: 2026-01-03
RZLT [bullish]
Rezolute, Inc.
-11.16%
current return
Author Info
JNap is Head of Research for Remsen Investors LP, a long/short biopharma fund and owner of Bio5C, an independent biopharma research service. Sign up for the newsletter.
Company Info
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States.
Market Cap
$200.8M
Pitch Price
$2.15
Price Target
N/A
Dividend
N/A
EV/EBITDA
-0.61
P/E
-2.37
EV/Sales
N/A
Sector
Biotechnology
Category
turnaround
Six Lottos For 2026 - Rezolute, Inc.
RZLT: Phase 3 CHI trial failed (45% vs 40% placebo reduction) due to flawed self-monitoring design, not drug efficacy. All subjects entered extension study. Separate THI indication shows promise - 5/5 compassionate use patients met endpoint (4 discontinued IV glucose). Phase 3 upLIFT data 2H26.
Read full article (3 min)